Drug Trial Radar · NCT07304011
Olutasidenib With Azacitidine Followed by Olutasidenib Maintenance for the Treatment of IDH1-mutated Acute Myeloid Leukemia in Patients With Prior Treatment With Venetoclax Plus a Hypomethylating Agent
Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
28
Planned (sponsor's estimate)
Start
Dec 17, 2025
Primary completion
Dec 1, 2027
Study completion Dec 1, 2029
Sponsor
- Lead sponsor
- University of California, DavisAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Dec 26, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II trial studies how well giving olutasidenib with azacitidine, followed by olutasidenib maintenance, works in treating patients with IDH1-mutated acute myeloid leukemia (AML) who have received prior treatment with venetoclax plus a hypomethylating agent (HMA-Ven). Olutasidenib and azacitidine may inhibit the growth of cancer cells by blocking certain enzymes required for cell growth. Maintenance therapy can help prevent or delay cancer from coming back. Olutasidenib with azacitidine followed by olutasidenib maintenance may be effective in treating patients with IDH1-mutated AML who have received prior HMA-Ven.
Conditions
- Acute Myeloid Leukemia
Interventions
AzacitidineDrug
Given IV or SC
OlutasidenibDrug
Given PO
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment failureTime frame: At 12 months from complete response (CR)/complete remission with incomplete count recovery (CRi)
- Median time to treatment failureTime frame: From CR/CRi through death due to AML, relapse, or treatment discontinuation due to adverse event, assessed up to 4 years
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
UCLA Jonsson Comprehensive Cancer Center
Los Angeles, California · Not yet recruiting
UCI Health Chao Family Comprehensive Cancer Center
Orange, California · Recruiting
University of California Davis Comprehensive Cancer Center
Sacramento, California · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.